Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel VIVORYON THERAPEUTICS N.V. AEX:VVY.NL, NL00150002Q7

Laatste koers (eur) Verschil Volume
2,210   -0,045   (-2,00%) Dagrange 2,210 - 2,285 37.761   Gem. (3M) 177K

Vivoryon is de naam. Daarom nieuw draadje

6.265 Posts
Pagina: «« 1 ... 227 228 229 230 231 ... 314 »» | Laatste | Omlaag ↓
  1. forum rang 7 lucas D 6 september 2021 12:39
    Vivoryon Therapeutics:

    2020:
    31 dec 9,010 = ijkpunt einde maand winst/verlies
    2021:
    29 januari slotkoers 13,904 = + 54,3%
    26 februari slotkoers 14,470 = + 60,6%
    31 maart slotkoers 15,200 = + 68,6%
    30 april slotkoers 14,850 = + 63,1%
    31 mei slotkoers 13,546 = + 50,4, %
    30 juni slotkoers 18,000 = + 99,8%
    30 juli slotkoers 19,012 = + 111,2%
    31 augustus slotkoers 21,200 = + 135,5 %

    30 augustus 20,235 : volume 39851
    31 augustus 21,200 : volume 54003
    01 september 22,000 : volume 123010
    02 september 21,805 : volume 46517
    03 september 21,700 : volume 4602

    Deze week een slotkoers van 21,700 dat is 1,680 hoger dan de voorgaande beursweek.

    Nieuws:
    Blijft staan:

    De slotkoers augustus is 2,088 hoger gesloten dan de slotkoers van juli

    Hoogste dagkoers deze week 22,580 laagste dagkoers deze week 19,75 verschil 2,83
    Volgende week weer een week met nieuwe kansen
  2. forum rang 7 lucas D 10 september 2021 11:22
    Vivoryon Therapeutics N.V. / Key word(s): Conference
    09.09.2021 / 16:41
    The issuer is solely responsible for the content of this announcement.
    Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    Halle (Saale) / Munich, Germany, September 9, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced today that Ulrich Dauer, PhD, the Company's Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday September 13, 2021, at 7:00 am ET.

    A replay of the webcast can be accessed from the Presentations & Webcasts page under News and Events on Vivoryon's website, www.vivoryon.com. The replay will be archived on Vivoryon's website for 30 days after the call.

    ###

    For more information, please contact:
    Investor Contact
    Vivoryon Therapeutics N.V.
    Dr. Manuela Bader, Director IR & Communication
    Tel: +49 (0)345 555 99 30
    Email: IR@vivoryon.com

    Media Contact
    Trophic Communications
    Valeria Fisher / Sophia Hergenhan
    Tel: +49 175 8041816
    Email: vivoryon@trophic.eu

    About Vivoryon Therapeutics N.V.
    Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com


    ________________________________________
    09.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de
    ________________________________________
6.265 Posts
Pagina: «« 1 ... 227 228 229 230 231 ... 314 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.